// App-Quantinova.ai

102.0 : Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).

Researchers

Presenter

  • Mayur Amonkar

Principal Investigators

  • David Gomez-Ulloa

  • Smita Kothari

  • Winson Y. Cheung

  • Ian Chau

  • John Raymond Zalcberg

  • Nuria Lara

  • Alfredo Falcone

Medical Centers

  • Merck & Co., Inc., North Wales, PA

  • VHIO, Barcelona, Spain

  • Center for Observational and Real World Evidence, Merck & Co. Inc., Kenilworth, NJ

  • BC Cancer Agency, Vancouver, BC, Canada

  • The Royal Marsden Hospital, London, United Kingdom

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • IQVIA Real World Insights, Basel, Switzerland

  • Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy

Locations

  • United States

  • Spain

  • Canada

  • United Kingdom

  • Australia

  • Switzerland

  • Italy

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved